Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Creative Commons License

Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., YALÇIN B., Dee R., van Noesel M. M., ...Daha Fazla

CLINICAL CHEMISTRY, cilt.55, sa.7, ss.1316-1326, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 7
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1373/clinchem.2008.117945
  • Dergi Adı: CLINICAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1316-1326
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity.